Mannkind Corp

NASDAQ: MNKD
$5.60
+$0.07 (+1.2%)
Real Time Data Delayed 15 Min.

MNKD Chart and Intraday Price

MNKD Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,216.88M USD
Shares Outstanding 270,418,000
MannKind Corporation is a pioneering biopharmaceutical firm dedicated to creating inhaled therapeutic products for diabetes and rare lung diseases. Its flagship product, Afrezza, is an innovative inhaled insulin offering a new approach to glycemic control in adults. Additionally, MannKind is developing treatments for pulmonary arterial hypertension and other serious lung conditions. With strategic partnerships for global distribution and a commitment to advancing respiratory health, MannKind stands at the forefront of inhalation technology for medical treatments.

MNKD Articles

24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.